Maze Therapeutics, a US-based precision medicines developer co-founded by researchers from Harvard University, Stanford University and University of California, San Francisco, procured $190m in funding led by Matrix Capital Management yesterday.
General Catalyst, Andreesen Horowitz’s Bio+Health, Woodline Partners, Casdin Capital, City Hill Ventures, Foresite Capital, Driehaus Capital Management, Moore Strategic Ventures, Terra Magnum Capital Partners, NS Investments and unnamed others took part in the round.
Maze Therapeutics is working on treatments for genetically defined diseases with a high unmet need, and the company currently has nine programmes in its pipeline.
Its three most advanced assets target Pompe disease, chronic kidney disease and amyotrophic lateral sclerosis. It expects to move its proposed therapy for Pompe disease into clinical trials in the first half of 2022, and the additional funding will also allow Maze to expand its platform.
Andy Tran, biotech investor at Matrix Capital Management, will join Maze’s board.
Maze launched in February 2019 with $191m in funding co-led by Third Rock Ventures and Arch Venture Partners.
That round also included GV and Alexandria Venture Investments, respective vehicles for technology conglomerate Alphabet and life sciences real estate investment trust Alexandria Real Estate Equities. Foresite Capital, Casdin Capital and unnamed others filled out the round.
City Hill Ventures subsequently committed an undisclosed sum in October 2019 in conjunction with the appointment of its founder and managing director Jonathan Lim to Maze’s board of directors.
